Return to search

Mirabilis Extends Series A

Mirabilis Medica Inc., a Seattle-based developer of technology that allows physician to destroy pathological tissue deep inside the body without damaging the intervening tissue, has raised $10.5 million in additional Series A funding. The round had held a $4 million first close last year from Charter Life Sciences and vSpring Capital. The extension was led by Arboretum Ventures, and also included Split Rock Partners, Dow Venture Capital and an individual angel. www.mirabilismedica.com